Vertex Pharmaceuticals Inc / Ma

0 products tracked · names used in filings: Vertex Pharmaceuticals Inc / Ma

Upcoming milestones

Mon 30 Nov 2026🇺🇸 PDUFA datecompany-announcedin 16 days

povetacicept: PDUFA target action date (IgA nephropathy (IgAN), accelerated approval)

Vertex Pharmaceuticals Inc / Ma (VRTX); povetacicept; BLA; status: set; "FDA, with an assigned PDUFA target action date of November 30, 2026."; filed 2026-11-02 · source

Recent milestones

No recent milestones.

Products

No products recorded.

Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.